257 related articles for article (PubMed ID: 26831663)
1. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
2. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
3. Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer.
Yoon G; Kim SM; Kim HJ; Seo AN
Tumour Biol; 2016 Mar; 37(3):3571-80. PubMed ID: 26456957
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
[TBL] [Abstract][Full Text] [Related]
5. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
[TBL] [Abstract][Full Text] [Related]
6. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
[TBL] [Abstract][Full Text] [Related]
10. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
[TBL] [Abstract][Full Text] [Related]
14. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
18. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
19. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
[TBL] [Abstract][Full Text] [Related]
20. Extramural perineural invasion in pT3 and pT4 rectal adenocarcinoma as prognostic factor after preoperative chemoradiotherapy.
Lino-Silva LS; Salcedo-Hernández RA; España-Ferrufino A; Ruiz-García EB; Ruiz-Campos M; León-Takahashi AM; Meneses-García A
Hum Pathol; 2017 Jul; 65():107-112. PubMed ID: 28526604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
